NIPT Prenatal Safe
PrenatalSafe® 5 — Non-Invasive Prenatal Test (NIPT) — £285
PrenatalSafe® 5 is a safe, accurate, non-invasive prenatal blood test developed by Eurofins Genoma. It analyses cell-free fetal DNA (cfDNA) in the mother's bloodstream to screen for the most common chromosomal conditions affecting pregnancy — with no risk of miscarriage.
The package costs £285, including your private GP consultation, the blood test, accredited laboratory analysis, and written GP comments on your results. A £25 prepayment is taken at booking and fully deducted from the package price when you proceed.
What PrenatalSafe® 5 screens for
Trisomy 21 — Down syndrome
Trisomy 18 — Edwards syndrome
Trisomy 13 — Patau syndrome
Sex chromosome aneuploidies — including Turner and Klinefelter syndromes
Fetal sex determination — available as an option
PrenatalSafe® 5 is the mid-tier option in the PrenatalSafe® range. For broader screening — microdeletions, additional chromosomes, or genome-wide analysis — our SafeKaryo Plus and SafeKaryo Plus COMPLETE packages may suit you better.
How the test works
A simple maternal blood sample is taken from your arm — no special preparation needed. The sample is processed using Next Generation Sequencing at Eurofins Genoma's accredited laboratories. Results are typically available within 5–7 working days.
The test can be performed from around 10 weeks of pregnancy. It is not suitable for dichorionic twin pregnancies — we'll confirm suitability at consultation. If you are Rh-negative and your partner is Rh-positive, the test can be combined with the RhSafe® test at no additional cost.
Important: a screening, not diagnostic, test
A low-risk result is reassuring but does not exclude all chromosomal or genetic conditions. A high-risk result indicates an increased likelihood and should be confirmed with diagnostic testing (such as CVS or amniocentesis). Your GP will explain this fully before you decide to test.
Pre-test consultation and informed consent
Your private GP consultation before the test ensures you understand what NIPT can and cannot detect, what each result means, and what follow-up options might be considered. A GMC-registered clinician reviews every report and provides written comments.
Clinical follow-up and counselling
If a result is high-risk, we will contact you promptly at no additional charge to discuss next steps, including referral to fetal medicine and specialist genetic counselling services. A follow-up consultation is also available from £50 (phone/video) or £80 (in person). With your consent, we can liaise with your maternity team or NHS GP.
Book your test
Contact us to book or to discuss whether PrenatalSafe® 5 is right for your pregnancy. Appointments are available at our Northwest Health branch.
Northwest Health is registered with and regulated by the Care Quality Commission.
PrenatalSafe® Karyo Plus — Genome-Wide NIPT — £800
PrenatalSafe® Karyo Plus — Genome-Wide NIPT — £800
PrenatalSafe® Karyo Plus is an advanced, non-invasive prenatal test developed by Eurofins Genoma. It analyses cell-free fetal DNA (cfDNA) in the mother's bloodstream to deliver genome-wide screening of all 23 pairs of chromosomes — alongside the most clinically important microdeletion syndromes — with no risk of miscarriage.
The package costs £800, including your private GP consultation, the blood test, accredited laboratory analysis, and written GP comments on your results. A £25 prepayment is taken at booking and fully deducted from the package price when you proceed.
What Karyo Plus screens for
All 23 pairs of chromosomes — trisomies 21, 18, 13, rarer trisomies, and sex chromosome aneuploidies such as Turner and Klinefelter syndromes
Fetal chromosomal imbalances — clinically significant duplications and deletions
Microdeletion syndromes — including 22q11.2 (DiGeorge), 1p36, Cri-du-Chat, Wolf-Hirschhorn, Prader-Willi, and Angelman
Fetal sex determination — available as an option
This level of screening is more comprehensive than standard NIPT panels and is best suited to those wanting the most thorough non-invasive assessment available, or with specific risk factors discussed at consultation.
How the test works
A simple maternal blood sample is taken from your arm — no special preparation needed. The sample is processed using Next Generation Sequencing at Eurofins Genoma's accredited laboratories. Results are typically available within 7–10 working days.
The test can be performed from around 10 weeks of pregnancy and is suitable for singleton and most twin pregnancies — eligibility confirmed at consultation. If you are Rh-negative and your partner is Rh-positive, it can be combined with the RhSafe® test at no additional cost.
Important: a screening, not diagnostic, test
A low-risk result is reassuring but does not exclude all chromosomal or genetic conditions. A high-risk result should be confirmed with diagnostic testing (CVS or amniocentesis). Because Karyo Plus screens across a much broader range of conditions, it can occasionally identify rare findings of uncertain significance — your GP will discuss this fully before you decide to test.
Pre-test consultation and informed consent
Genome-wide screening has significant clinical and psychological implications. Your private GP consultation before the test ensures you understand what Karyo Plus can and cannot detect, what each result means, and what follow-up options might be considered. A GMC-registered clinician reviews every report.
Clinical follow-up and counselling
If a result is high-risk or uncertain, we will contact you promptly at no additional charge to discuss next steps, including referral to fetal medicine and specialist genetic counselling. A follow-up consultation is also available from £50 (phone/video) or £80 (in person).
Book your test
Contact us to book. Appointments are available at our Northwest Health branch.
Northwest Health is registered with and regulated by the Care Quality Commission.
PrenatalSafe® Karyo Plus COMPLETE — Genome-Wide NI
PrenatalSafe® Karyo Plus COMPLETE — Genome-Wide NIPT with Single-Gene Disorder Screening — £1,400
PrenatalSafe® Karyo Plus COMPLETE is the most comprehensive non-invasive prenatal test in the PrenatalSafe® range, developed by Eurofins Genoma. It combines genome-wide chromosomal screening with single-gene disorder screening (GeneSafe) — analysing cell-free fetal DNA from a simple maternal blood sample, with no risk of miscarriage.
The package costs £1,400, including your private GP consultation, the blood test, accredited laboratory analysis, and written GP comments on your results. A £25 prepayment is taken at booking and fully deducted from the package price when you proceed.
What COMPLETE screens for
Chromosomal screening (genome-wide)
All 23 pairs of chromosomes — trisomies 21, 18, 13, rarer trisomies, and sex chromosome aneuploidies (Turner, Klinefelter, and others)
Fetal chromosomal imbalances — clinically significant duplications and deletions
Microdeletion syndromes — including 22q11.2 (DiGeorge), 1p36, Cri-du-Chat, Wolf-Hirschhorn, Prader-Willi, and Angelman
Fetal sex determination — optional
Single-gene disorder screening (GeneSafe)
